Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

Valion Bio confirmed that the U.S. House Armed Services Committee’s FY27 NDAA report directs the Department of Defense to develop a plan for prioritizing radiation and nuclear countermeasures that are both prophylactic and therapeutic. This policy directive aligns with Valion Bio’s lead candidate, Entolimod, which has demonstrated efficacy as both a radioprotectant and radiomitigant in non-human primate studies under the FDA’s Animal Rule.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.